Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib PK and Safety with LBM and PPIs
NCT02439723Phase 1Withdrawn
- Sponsor
- American Health Staffing Group
- Start
- Mar 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of regorafenib in metastatic solid tumor and Nonhematologic neoplasms, sponsored by American Health Staffing Group. Primary endpoint: Peak plasma concentration of regorafenib at 5 days. Planned start Mar 2016; status: withdrawn.
02
Drugs
regorafenib
03
Conditions
metastatic solid tumorNonhematologic neoplasms
Beyond the preview
Go deeper on NCT02439723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02439723.